Orchard Therapeutics PLC
Stefano Bruni has an extensive background in medical affairs and pediatric medicine spanning over three decades. Stefano has held various leadership roles at organizations like Orchard Therapeutics, Sanofi Genzyme, and Genzyme Srl. Their experience includes leading medical teams, engaging with key opinion leaders, managing pre-clinical research projects, and developing strategies at regional and international levels. Additionally, Stefano has a strong academic background as a pediatrician and researcher, with a focus on rare genetic diseases and respiratory conditions.
Stefano Bruni obtained a Specialist degree in Pediatrics from the Polytechnic University of Marche in 2004. Prior to that, they completed their Laurea in Medicina e Chirurgia e Specializzazione in Pediatria from Università di Bologna e Università politecnica delle Marche.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.